


1. A pharmaceutical preparation characterized by a content of at least one compound of general formula (I)



wherein R_1 and R_2 are each independently of each other a straight-chain or branched alkyl residue having 1 to 30 carbon atoms, a straight-chain or branched alkenyl residue having 2 to 30 carbon atoms, a monocyclic or polycyclic alkyl residue having 3 to 30 carbon atoms, a monocyclic or polycyclic alkenyl residue having 4 to 30 carbon atoms, or a monocyclic or polycyclic aromatic residue having 6 to 30 carbon atoms, these residues being optionally substituted by one or several substituents.

2. The pharmaceutical preparation according to claim 1, wherein in the compound of formula (I) R_1 and R_2 are a straight-chain C_{1-14} alkyl residue or a C_{3-14} cycloalkyl residue each.

-
3. (Amended) The pharmaceutical preparation according to claim 1, wherein in the compound of formula (I) R_1 and R_2 are CH_3CH_2 each.
-

4. The pharmaceutical preparation according to claim 1, wherein the compound of formula (I) is dimethylxanthogenate platinum (II) complex or diethylxanthogenate platinum (II) complex.
5. The pharmaceutical preparation according to claim 1, comprising additionally an immunosuppressive compound selected from the group consisting of cyclosporine, rapamycin, 15-deoxyspergualine, OKT3 and azathioprine.

6. The pharmaceutical preparation according to claim 1, comprising additionally cytokines, interferon or further cytostatic agents.
7. The pharmaceutical preparation according to claim 1, provided in a unit dosage form for administration to a mammal which requires treatment with an anticancer agent.
8. The pharmaceutical preparation according to claim 1, further comprising a pharmaceutically compatible inert carrier or a diluent.
11. A process for the production of a pharmaceutical preparation according to claim 1, characterized in that the compound according to formula (I) is mixed with a pharmaceutically compatible carrier or diluent.

12. (Amended) A method of treating cancerous disease, comprising administering the preparation of claim 1 in an amount effective to treat said cancerous disease.

13. (Amended) The method of claim 12, wherein said cancerous disease is parvocellular bronchial carcinoma or colorectal carcinoma.

14. (Amended) The pharmaceutical preparation according to claim 6, wherein the further cytostatic agent is cisplatin, methotrexate, aminopterin, dacarbazine, nitroso urea compounds, fluorouracil, bleomycin, daunomycin, daunorubicin, doxorubicin, mithramycin, or mitomycin C.

15. (Amended) The method according to claim 12, wherein said cancerous disease is selected from testicular tumors, ovarian carcinomas, bladder carcinomas, colonic carcinomas, prostatic carcinomas, parvocellular and non-parvocellular bronchial carcinomas, carcinomas of the cephalic and cervical parts, carcinomas of the thoracic and abdominal regions, cervical and endometrial carcinomas, sarcomas, melanomas and leukemias.